Know Cancer

forgot password

Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors

Phase 2
18 Years
Open (Enrolling)
Renal Cell Carcinoma

Thank you

Trial Information

Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors

OUTLINE: This is a multi-center study.

Phase I: Patients will be accrued in the classic 3 patients per dose per cohort design,
21-day cycle

- Dose Level 1 Everolimus 10 mg BNC105P 4.2 mg/m2

- Dose Level 2 Everolimus 10 mg BNC105P 8.4 mg/m2

- Dose Level 3 Everolimus 10 mg BNC105P 12.6 mg/m2

- Dose Level 4 Everolimus 10 mg BNC105P 16 mg/m2

Phase II: Patients will be randomized 1:1 to Arm A or Arm B

Combination Arm A: Everolimus 10 mg + BNC105P MTD (from Phase 1 study) 21 day cycle

Sequential Arm B: Everolimus 10 mg 21 day cycle

- Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or
intolerable toxicity on everolimus therapy.

Karnofsky Performance Score (KPS) ≥70 within 7 days prior to registration for protocol

Life Expectancy: Not specified


- White blood cell count (WBC) > 3.5 K/mm3

- Hemoglobin (Hgb) > 8.5 g/dL

- Platelets > 100 K/mm3

- Absolute neutrophil count (ANC) > 1.5 K/mm3


- Total Bilirubin < 1.25 x ULN

- Aminotransferase (AST and ALT) < 2.5 x ULN


- Serum Creatinine < 2.5 x ULN (upper limit normal)


- No significant cardiovascular events within 6 months (CVA, CAD, peripheral arterial
obstruction, arrhythmias, cardiac dysfunction) of registration for protocol therapy

- No history of clinical CHF or LVEF <50% by Echo (or MUGA) within 30 days prior to
registration for protocol therapy.

Inclusion Criteria:

- Histological or cytological proof of component (any percent) of clear cell RCC (renal
cell carcinoma).

- Metastatic or locally advanced unresectable RCC. NOTE: Prior nephrectomy is not

- Progressive disease after 1-2 prior VEGF-directed tyrosine kinase inhibitors (TKIs).

- Measurable disease according to RECIST and obtained by imaging within 30 days prior
to registration for protocol therapy.

- Written informed consent and HIPAA authorization for release of personal health

- Age > 18 years at the time of consent.

- Females of childbearing potential and males must be willing to use an effective
method of contraception (hormonal or barrier method of birth control; abstinence)
from the time consent is signed until 4 weeks after treatment discontinuation.

- Females of childbearing potential must have a negative pregnancy test within 7 days
prior to registration for protocol therapy.

Exclusion Criteria:

- No active brain metastases. Patients with neurological symptoms must undergo a head
CT scan or brain MRI to exclude brain metastasis within 30 days prior to registration
on protocol therapy. NOTE: A patient with prior brain metastasis are eligible if
they have completed their radiation treatment for brain metastasis ≥30 days prior to
registration for protocol therapy, are off steroids, and are asymptomatic.

- No other currently active malignancy.

- No treatment with any investigational agent within 14 days prior to registration for
protocol therapy. NOTE: If treated with investigational agent within 14 days prior
to registration, AE must be resolved back to baseline.

- Prior cancer treatment must be completed at least 14 days prior to registration for
protocol therapy and the patient must have recovered from the acute toxic effects of
the regimen. With the exception of Bevacizumab treatment, which must be completed 30
days prior to registration for protocol therapy.

- Prior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart
in the study procedure manual (SPM)] allowed if completed within 30 days prior to
registration for protocol therapy.

- Corrected QT interval (QTc) ≤ 450 msec at least 7 days prior to registration for
protocol therapy.

- No clinically significant infections as judged by the treating investigator.

- No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent

- No collecting duct, medullary or sarcomatoid histology.

- No prior treatment with temsirolimus or everolimus in the phase II component of the
study. NOTE: Prior treatment with these agents is permitted in the phase I component
of the study.

- No use of full dose, therapeutic anti-coagulation with warfarin or related
anti-coagulants or unfractionated or low molecular weight heparins.

- No uncontrolled hypertension (BP >150/100mmHg despite full doses of 1
anti-hypertensive medication).

- No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of
registration for protocol therapy.

- No grade 2 or greater peripheral neuropathy.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase I: To determine maximum tolerated dose and toxicities of BNC105P in combination with everolimus.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Thomas Hutson, D.O.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group


United States: Food and Drug Administration

Study ID:

HOG GU09-145



Start Date:

January 2010

Completion Date:

June 2013

Related Keywords:

  • Renal Cell Carcinoma
  • Metastatic Kidney Cancer
  • BNC105P
  • Carcinoma
  • Carcinoma, Renal Cell



Roswell Park Cancer Institute Buffalo, New York  14263
Mayo Clinic Rochester, Minnesota  55905
Geisinger Medical Center Danville, Pennsylvania  17822-0001
Joe Arrington Cancer Research and Treatment Center Lubbock, Texas  79410-1894
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire  03756
Mount Nittany Medical Center State College, Pennsylvania  16803
Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana  46202-5289
Cancer and Hematology Centers of Western Michigan Grand Rapids, Michigan  49546
St. Joseph Mercy Hospital Pontiac, Michigan  48341-2985
City of Hope Duarte, California  91010
Genesis Cancer Center Hot Springs, Arkansas  71913
Cascade Cancer Center Kirkland, Washington  98034-3013
Broward Oncology Associates Ft. Lauderdale, Florida  33308
Northeast Georgia Cancer Care, LLC Athens, Georgia  30607
Tufts Medical Center Boston, Massachusetts  02111
Methodist Cancer Center Omaha, Nebraska  68114
Texas Oncology, PA Dallas, Texas  75246-2006
Compassionate Cancer Care medical Group, Inc. Fountain Valley, California  92708
Somerset Hematology Oncology Associates Somerset, New Jersey  08873
Hematology and Oncology Associates of Rhode Island Cranston, Rhode Island  02920
Kentucky Cancer Clinic Pikeville, Kentucky  41501
Allegheny Cancer Center Pittsburgh, Pennsylvania  15212-4772
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Rockwood Clinic Spokane, Washington  99220
Metairie Oncologists Metairie, Louisiana  70006
Medical & Surgical Specialists, LLC Galesburg, Illinois  61401
Cancer Center of Kansas Wichita, Kansas  67214
New York Oncology Hematology, PC Albany, New York  12208
Robert A. Moss, M.D., FACP, Inc. Fountain Valley, California  92708
Lynchburg Hematology Oncology Clinic, Inc. Lynchburg, Virginia  24501
Northwest Alabama Cancer Center Muscle Shoals, Alabama  35661
Compassionate Cancer Care Medical Group Corona, California  92882
South Carolina Cancer Specialists Hilton Head Island, South Carolina  29925
Medical Oncology LLC Baton Rouge, Louisiana  70809
MUSC Hollings Cancer Center Charleston, South Carolina  29425
Oncology Hematology Associates of SW Indiana Evansville, Indiana  47714
Berks Hematology Oncology Associates West Reading, Pennsylvania  19611
Community Regional Cancer Center Indianapolis, Indiana  46256
Fort Wayne Oncology & Hematology, Inc Fort Wayne, Indiana  46815
Kootenai Cancer Center Post Falls, Idaho  83854
Northwestern University, Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois  60611
Mercy Physicians of Oklahoma Tulsa, Oklahoma  74136
The Jones Clinic, Pc Germantown, Tennessee  38138
Presbyterian Medical Group Albuquerque, New Mexico  87110
Hematology Oncology Associates of Rockland Nyack, New York  10960
Signal Point Clinical Research Center Middletown, Ohio  45042
Monroe Medical Associates Munster, Indiana  46321
Purchase Cancer Group Paducah, Kentucky  42002
Good Samaritan Hospital Los Angeles, California  90017
Methodist Hospital Research Institute Houston, Texas  77030
Ocala Cancer Institute Ocala, Florida  34471
Gettysburg Cancer Center Gettysburg, Pennsylvania  17325
CTRC at the UT Health Science Center at San Antonio San Antonio, Texas  78229
University of Florida, Shands Cancer Center Gainesville, Florida  32610
IU Health Goshen Goshen, Indiana  46527
IU Health Central Indiana Cancer Centers Indianapolis, Indiana  46219
Horizon Oncology Research Lafayette, Indiana  47905
IU Health at Ball Memorial Hospital Cancer Center Muncie, Indiana  47303
Siouxland Hematology Oncology Associates, LLP, Nylen Cancer Center Sioux City, Iowa  51101
Metro Health Cancer Care Wyoming, Michigan  49519
University of New Mexico Cancer Care Alliance Albuquerque, New Mexico  87131
Tisch Cancer Institute at Mount Sinai Medical Center New York, New York  10029
Houston Cancer Center Houston, Texas  77055
Harrison HealthPartners Bremerton Hematology & Oncology Bremerton, Washington  98310
University of Washington, Seattle Cancer Care Alliance Seattle, Washington  98109
Group Health Medical Centers Seattle, Washington  98109
University of Wisconsin, Clinical Cancer Center Milwaukee, Wisconsin  53226
Cancer Care Centers of Brevard Rockledge, Florida  32955
American Institute of Research Whittier, California  90603
Sletten Cancer Specialists Great Falls, Montana  59405
Cancer Care Centers Of Florida Brooksville, Florida  34613
Providence Health System: Roy and Patricia Disney Family Cancer Center Burbank, California  91505
California Cancer Associates for Research and Excellence Fresno, California  93720
Marin Specialty Care Greenbrae, California  94904
UCLA Med - Hematology & Oncology Los Angeles, California  90095
Centura Health Research Center Denver, Colorado  80210
Western Oncology & Hematology Golden, Colorado  80401
Cancer Care Centers of Florida: Brooksville Brooksville, Florida  34613
Cancer Specialists of North Florida Jacksonville, Florida  32256
Advanced Pharma CR, LLC Miami, Florida  33136
Dublin Hematology & Oncology Care Dublin, Georgia  31021
Edward H. Kaplan, M.D., & Associates Skokie, Illinois  60076
Deaconess Clinic Evansville, Indiana  47713
Bozeman Deaconness Cancer Center Bozeman, Montana  59715
Trinitas Regional Medical Center Elizabeth, New Jersey  07202
NYU Langone Arena Oncology Lake Success, New York  11042
First Health of the Carolinas Pinehurst, North Carolina  28374
Lawrence M. Stallings, M.D. Wooster, Ohio  44691
Willamette Valley Cancer Institute Springfield, Oregon  97477
Texas Oncology: Austin North Austin, Texas  78758
Texas Oncology: Bedford Bedford, Texas  76022
Texas Oncology: Fort Worth Fort Worth, Texas  76104
Texas Oncology: Houston Memorial City Houston, Texas  77024